| Issue Date | Title | Author(s) |
| 2019 | All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china | Wei, Lai; Xu, Xiaoyuan; Guan, Yujuan; Zheng, Sujun; Sheng, Ji-Fang; Yang, Xingxiang; Ma, Yuanji; Huang, Yan; Kang, Yi; Wen, Xiaofeng; Li, Jun; Tan, Youwen; He, Qing; Xie, Qing; Wang, Maorong; An, Ping; Gong, Guozhong; Liu, Huimin; Ning, Qin; Hua, Rui; Ning, Bo; Xie, Wen; Zhang, Jiming; Huang, Wenxiang; Yang, Yongfeng; Lin, Minghua; Zhao, Yingren; Yu, Yanhong; Jia, Ji-Dong; Yang, Dongliang; Chen, Liang; Ye, Yinong; Nan, Yuemin; Gong, Zuojong; Zhang, Quan; Hu, Peng; Wang, Fu-Sheng; Li, Yongguo; Li, Dongliang; Jia, Zhansheng; Hou, Jinlin; Chen, Chengwei; Wu, Jinzi |
| 2018 | Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study | Zhu, Dalong; Gan, Shenglian; Liu, Yu; Ma, Jianhua; Dong, Xiaolin; Song, Weihong; Zeng, Jiao'e; Wang, Guixia; Zhao, Wenjuan; Zhang, Qiu; Li, Yukun; Fang, Hui; Lv, Xiaofeng; Shi, Yongquan; Tian, Haoming; Ji, Linong; Gao, Xin; Zhang, Lihui; Bao, Yuqian; Lei, Minxiang; Li, Ling; Zeng, Longyi; Li, Xiaoying; Hou, Xinghua; Zhao, Yu; Hu, Tianxin; Ge, Xiaoyun; Zhao, Guiyu; Li, Yongguo; Zhang, Yi; Chen, Li |
| 2018 | Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China | Wei, Lai; Xu, Xiaoyun; Guan, Yujuan; Zheng, Sujun; Sheng, Jifang; Yang, Xingxiang; Ma, Yuanji; Huang, Yan; Kang, Yi; Wen, Xiaofeng; Li, Jun; Tan, Youwen; He, Qing; Xie, Qing; Wang, Maorong; An, Ping; Gong, Guozhong; Liu, Huimin; Ning, Qin; Hua, Rui; Ning, Bo; Xie, Wen; Zhang, Jiming; Huang, Wenxiang; Yang, Yongfeng; Lin, Minghua; Zhao, Yingren; Yu, Yanhong; Jia, Jidong; Yang, Dongliang; Chen, Liang; Ye, Yinong; Nan, Yuemin; Gong, Zuojiong; Zhang, Quan; Hu, Peng; Wang, FuSheng; Li, Yongguo; Li, Dongliang; Jia, Zhansheng; Hou, Jinlin; Chen, Chengwei |
| 2018 | Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China | Wei, Lai; Xu, Xiaoyun; Guan, Yujuan; Zheng, Sujun; Sheng, Jifang; Yang, Xingxiang; Ma, Yuanji; Huang, Yan; Kang, Yi; Wen, Xiaofeng; Li, Jun; Tan, Youwen; He, Qing; Xie, Qing; Wang, Maorong; An, Ping; Gong, Guozhong; Liu, Huimin; Ning, Qin; Hua, Rui; Ning, Bo; Xie, Wen; Zhang, Jiming; Huang, Wenxiang; Yang, Yongfeng; Lin, Minghua; Zhao, Yingren; Yu, Yanhong; Jia, Jidong; Yang, Dongliang; Chen, Liang; Ye, Yinong; Nan, Yuemin; Gong, Zuojiong; Zhang, Quan; Hu, Peng; Wang, FuSheng; Li, Yongguo; Li, Dongliang; Jia, Zhansheng; Hou, Jinlin; Chen, Chengwei |
| 2019 | Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naive Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China | Xu, Xiaoyuan; Feng, Bo; Guan, Yujuan; Zheng, Sujun; Sheng, Jifang; Yang, Xingxiang; Ma, Yuanji; Huang, Yan; Kang, Yi; Wen, Xiaofeng; Li, Jun; Tan, Youwen; He, Qing; Xie, Qing; Wang, Maorong; Anl, Ping; Gong, Guozhong; Liu, Huimin; Nine, Qin; Hua, Rui; Ning, Bo; Xie, Wen; Zhang, Jiming; Huang, Wenxiang; Yang, Yongfeng; Lin, Minghua; Zhao, Yingren; Yu, Yanhong; Jia, Jidong; Yang, Dongliang; Chen, Liang; Ye, Yinong; Nan, Yuemin; Gong, Zuojiong; Zhang, Quan; Hu, Peng; Wang, Fusheng; Li, Yongguo; Li, Dongliang; Jia, Zhansheng; Hou, Jinlin; Chen, Chengwei; Wu, Jinzi J.; Wei, Lai |
| 2019 | THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL | Wei, Lai; Xu, Xiaoyuan; Zheng, Sujun; Guan, Yujuan; Sheng, Jifang; Yang, Xingxiang; Ma, Yuanji; Huang, Yan; Kang, Yi; Wen, Xiaofeng; Li, Jun; Tan, Youwen; He, Qing; Xie, Qing; Wang, Maorong; An, Ping; Gong, Guozhong; Liu, Huimin; Ning, Qing; Hua, Rui; Ning, Bo; Xie, Wen; Zhang, Jiming; Huang, Wenxiang; Yang, Yongfeng; Lin, Minghua; Zhao, Yingren; Yu, Yanhong; Jia, Jidong; Yang, Dongliang, Sr.; Chen, Liang; Ye, Yinong, Sr.; Nan, Yuemin; Gong, Zuojiong; Zhang, Quan; Hu, Peng; Wang, FuSheng; Li, Yongguo; Li, Dongliang; Jia, Zhansheng; Hou, Jinlin; Chen, Chengwei; Wu, Jinzi |
| 2019 | Incidence and Etiology of Drug-Induced Liver Injury in Mainland China | Shen, Tao; Liu, Yingxia; Shang, Jia; Xie, Qing; Li, Jun; Yan, Ming; Xu, Jianming; Niu, Junqi; Liu, Jiajun; Watkins, Paul B.; Aithal, Guruprasad P.; Andrade, Raul J.; Dou, Xiaoguang; Yao, Lvfeng; Lv, Fangfang; Wang, Qi; Li, Yongguo; Zhou, Xinmin; Zhang, Yuexin; Zong, Peilan; Wan, Bin; Zou, Zhengsheng; Yang, Dongliang; Nie, Yuqiang; Li, Dongliang; Wang, Yuya; Han, Xi'an; Zhuang, Hui; Mao, Yimin; Chen, Chengwei |
| 2017 | Pharmacodynamic subgroup analysis of glucose kinase activator (GKA) after 12 weeks of treatment with HMS5552 in T2DM patients in China | Zhu, Dalong; Gan, Shenglian; Liu, Yu; Ma, Jianhua; Dong, Xiaolin; Song, Weihong; Zeng, Jiaoe; Wang, Guixia; Zhao, Wenjuan; Zhang, Qiu; Li, Yukun; Fang, Hui; Lv, Xiaofeng; Shi, Yongquan; Tian, Haoming; Ji, Linong; Gao, Xin; Zhang, Lihui; Bao, Yuqian; Lei, Minxiang; Li, Ling; Zeng, Longyi; Li, Xiaoying; Hu, Tianxin; Zhao, Guiyu; Ge, Xiaoyun; Zhao, Yu; Hou, Xinghua; Li, Yongguo; Zhang, Yi; Chen, Li |
| 2017 | Pharmacodynamic subgroup analysis of glucose kinase activator (GKA) after 12 weeks of treatment with HMS5552 in T2DM patients in China | Zhu, Dalong; Gan, Shenglian; Liu, Yu; Ma, Jianhua; Dong, Xiaolin; Song, Weihong; Zeng, Jiaoe; Wang, Guixia; Zhao, Wenjuan; Zhang, Qiu; Li, Yukun; Fang, Hui; Lv, Xiaofeng; Shi, Yongquan; Tian, Haoming; Ji, Linong; Gao, Xin; Zhang, Lihui; Bao, Yuqian; Lei, Minxiang; Li, Ling; Zeng, Longyi; Li, Xiaoying; Hu, Tianxin; Zhao, Guiyu; Ge, Xiaoyun; Zhao, Yu; Hou, Xinghua; Li, Yongguo; Zhang, Yi; Chen, Li |
